Picture loading failed.

Anti-KIRD2 therapeutic antibody (Pre-made Lirilumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Lirilumab (INN) is a human monoclonal antibody designed for the treatment of cancer. It binds to KIR2DL1/2L3.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-316-1mg 1mg 3090
GMP-Bios-ab-316-10mg 10mg 21890
GMP-Bios-ab-316-100mg 100mg 148000
GMP-Bios-ab-316-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-KIRD2 therapeutic antibody (Pre-made Lirilumab biosimilar,Whole mAb)
INN Name Lirilumab
TargetKIRD2
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2012
Year Recommended2013
CompaniesNovo Nordisk;Bristol-Myers Squibb;Dana-Farber Cancer Institute;Innate Pharma;National Cancer Institute (USA);Ono Pharmaceutical;PrECOG;University of Texas M. D. Anderson Cancer Center
Conditions Approvedna
Conditions ActiveChronic lymphocytic leukaemia;Head and neck cancer;Myelodysplastic syndromes;Solid tumours;Bladder cancer
Conditions DiscontinuedAcute myeloid leukaemia;Hepatitis C;Haematological malignancies;Multiple myeloma;Lymphoma
Development TechMedarex UltiMAb Mouse